UNION therapeutics to present at 7th Annual Dermatology Drug Development Summit in Boston
Hellerup, Denmark, October 25, 2023 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced that Dr. Kim D. […]
UNION therapeutics announces presentation of new data on orismilast at the EADV Congress 2023
Late-breaking presentation of data from the OSIRIS IIT PoC study of oral orismilast in hidradenitis suppurativa (HS) at the European Academy of Dermatology and Venerology Congress 2023 Additional e-posters on […]
Announcement of topline results from the PROTECT-V platform study investigating niclosamide nasal spray to prevent COVID-19 infection in vaccinated but highly vulnerable patients
Hellerup, Denmark, June 16, 2023 – UNION therapeutics A/S, a privately-held, clinical stage, pharmaceutical development company focused on immunology and infectious disease, today announced topline results from the niclosamide arm […]
UNION therapeutics announces presentation of preliminary data on Phase 2a investigator-initiated study with orismilast at the 12th EHSF Conference and provides study update
Poster presentation of preliminary data from the Phase 2a investigator-initiated study OSIRIS at the 12th EHSF Conference Hidradenitis suppurativa (HS) is a scarring, painful, inflammatory skin disease with few or […]
First large-scale analysis confirms that vulnerable patients remain at increased fatality to COVID-19 despite availability of vaccines
Analysis includes data from UK Kidney Association (UKKA) on 9,388 COVID-19 cases among kidney patients in the UK of which 924 were fatal (Dec 2020 to March 2022) The analyses […]
UNION therapeutics announces two peer-reviewed publications of preclinical and clinical Phase 2a data on orismilast
New insights into the pharmacological properties of orismilast and Phase 2a data published in peer-reviewed journal JEADV Data supports orismilast’s potential as a first-in-class or best-in-class treatment for a range […]
UNION therapeutics to present at the Dermatology Summit 2023
UNION invited to present orismilast at the Dermatology Summit 2023 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class or best-in-class treatment for […]
UNION therapeutics and Innovent announce first subject dosed in a Chinese clinical Phase 1 study of orismilast, a novel PDE-4 inhibitor
Hellerup, Denmark and ROCKVILLE, M.D., Suzhou, China, 5 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, and Innovent […]
UNION therapeutics completes 62 million DKK private placement to support clinical program
Hellerup, Denmark, 1 December 2022 – UNION therapeutics A/S (UNION), a privately-held, multi-asset, clinical stage, pharmaceutical development company focused on immunology and infectious diseases, today announced the completion of a […]
UNION therapeutics to present at the 6th Annual Dermatology Drug Development Summit
Data on pharmacological properties of orismilast to be presented on 2nd of November 2022 Orismilast is a potent next-generation PDE4 inhibitor with broad anti-inflammatory properties in development as a first-in-class […]